Summit Trail Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$34.9M Buy
29,075
+692
+2% +$707K 0.44% 33
2026
Q1
$26.1M Buy
28,383
+7,823
+38% +$7.93M 0.37% 35
2025
Q4
$22.1M Sell
20,560
-906
-4% -$866K 0.38% 33
2025
Q3
$16.4M Buy
21,466
+2,244
+12% +$1.67M 0.23% 52
2025
Q2
$15M Buy
+19,222
New +$14.9M 0.26% 50
2024
Q4
Sell
-7,549
Closed -$6.69M 605
2024
Q3
$6.69M Buy
7,549
+718
+11% +$646K 0.17% 62
2024
Q2
$6.18M Sell
6,831
-777
-10% -$622K 0.16% 57
2024
Q1
$5.92M Buy
7,608
+644
+9% +$458K 0.16% 55
2023
Q4
$4.06M Sell
6,964
-87
-1% -$50.8K 0.13% 62
2023
Q3
$3.79M Buy
7,051
+416
+6% +$214K 0.14% 60
2023
Q2
$3.11M Buy
6,635
+3,531
+114% +$1.48M 0.12% 71
2023
Q1
$1.07M Buy
3,104
+634
+26% +$214K 0.04% 121
2022
Q4
$904K Buy
2,470
+196
+9% +$69.5K 0.04% 125
2022
Q3
$735K Buy
2,274
+653
+40% +$207K 0.04% 131
2022
Q2
$526K Buy
1,621
+627
+63% +$188K 0.03% 174
2022
Q1
$285K Buy
994
+1
+0.1% +$257 0.02% 257
2021
Q4
$274K Buy
+993
New +$252K 0.02% 242
2018
Q2
Sell
-2,967
Closed -$237K 574
2018
Q1
$237K Sell
2,967
-336
-10% -$27K 0.04% 333
2017
Q4
$279K Buy
+3,303
New +$281K 0.04% 338

Other funds holding LLY

Summit Trail Advisors's LLY Position: Q2 2026 in Review

Summit Trail Advisors increased its Eli Lilly (LLY) stake by 2.4% in Q2 2026, buying an estimated $707K and bringing the position to 29,075 shares worth $34.9M. The position accounts for 0.44% of the portfolio, ranked #33.

Summit Trail Advisors first reported a position in LLY in Q4 2017 and has held it in 19 quarters since. 4,614 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Summit Trail Advisors held 29,075 shares of Eli Lilly worth $34.9M as of Q2 2026.
  • Summit Trail Advisors bought 692 Eli Lilly shares in Q2 2026, an estimated $707K.
  • Eli Lilly made up 0.44% of Summit Trail Advisors's portfolio in Q2 2026, its #33 holding.
  • Summit Trail Advisors first reported a position in Eli Lilly in Q4 2017 and has held it in 19 quarters since.
  • 4,614 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.